Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NTLA-2001
NTLA-2001
Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug
Xtalks
Mon, 10/23/23 - 10:31 am
Intellia Therapeutics
FDA
NTLA-2001
ATTR with cardiomyopathy
Intellia's gene editing therapies both post early successes as evidence grows for CRISPR potential
Fierce Biotech
Fri, 09/16/22 - 10:53 am
Intellia Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
clinical trials
Regeneron
Intellia, LogicBio fuel hope for in vivo gene editing with new animal data in rare diseases: report
Fierce Biotech
Mon, 10/25/21 - 11:53 pm
Intellia Therapeutics
LogicBio Therapeutics
gene editing
NTLA-2001
ATTR amyloidosis
Intellia Aims Big with CRISPR Therapy to Cure ATTR
BioSpace
Tue, 10/20/20 - 10:44 am
Intellia Therapeutics
CRISPR
hereditary ATTR amyloidosis
NTLA-2001